Vitamin D and Omega-3 Inhibit Metabolic Syndrome

Key facts

Sponsor

University of Guelph

Principal Investigator

Kelly A Meckling, PhD

University of Guelph

Intervention

low glycemic diet(other)

Enrollment

40 enrolled

Eligibility

18-65 years · All sexes

Timeline

2011 – 2012

Study locations (1)

• University of Guelph, Guelph, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dysbetalipoproteinemia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07219602
  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
  NewAmsterdam Pharma

See all trials for Dysbetalipoproteinemia →